Enmotus Joins Dell/EMC’s Software and Peripherals (SnP) Program
Aug 01, 2017 11:55 am UTC| Business
ALISO VIEJO, Calif., Aug. 01, 2017 -- Enmotus, the market leader in Storage Automation and Analytics software (SAA), today announced that it has been added to the Dell/EMC Software and Peripherals program. Targeted for...
Exosome Diagnostics Announces New World Headquarters and Laboratory in Waltham, MA
Aug 01, 2017 11:50 am UTC| Business
Waltham, Mass., Aug. 01, 2017 -- Exosome Diagnostics, a leader in the liquid biopsy market, announced today that it has moved into a new worldwide headquarters and clinical laboratory in Waltham, MA. The state of the...
Aug 01, 2017 11:40 am UTC| Business
PLANTATION, Fla., Aug. 01, 2017 -- TradeStation, a Monex Group company and award-winning** online broker-dealer and futures commission merchant, announced today new pricing for futures for all new customers and all...
Affimed Reports Financial Results for Second Quarter 2017
Aug 01, 2017 11:31 am UTC| Business
Heidelberg, Germany, August 1, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results...
Aug 01, 2017 11:30 am UTC| Business
Global Phase 3 Program Expected to Commence Before End of Q3 2017 International Phase 3 Trials Entitled “ULTIMATE I” and “ULTIMATE II” to be Led by Lawrence Steinman, MD, of Stanford University NEW YORK, Aug. 01, 2017...
Flexion Therapeutics to Report Second-Quarter 2017 Financial Results on August 8, 2017
Aug 01, 2017 11:30 am UTC| Business
BURLINGTON, Mass., Aug. 01, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its second-quarter 2017...
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results
Aug 01, 2017 11:30 am UTC| Business
Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2nd Half On-track to Initiate Two Additional Phase 2 Trials Later This Year in Status Epilepticus and Moderate Postpartum...